Viruses in the treatment of malignant glioma

Expert Review of Neurotherapeutics

Volumn 7, Issue 4, 2007, Pages 321-324

  Everson, Richard G ^a   Gromeier, Mathias ^a   Sampson, John H ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTINEOPLASTIC AGENT; CANCER VACCINE; CYCLOPHOSPHAMIDE; GANCICLOVIR; ONCOLYTIC ADENOVIRUS; ONCOLYTIC HERPES VIRUS; ONCOLYTIC POLIOVIRUS; ONCOLYTIC VIRUS; ONYX 015; THYMIDINE KINASE; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VECTOR;

ADENOVIRUS; CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CLINICAL FEATURE; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DISEASE FREE SURVIVAL; DRUG ANTAGONISM; DRUG MECHANISM; DRUG SELECTIVITY; EDITORIAL; ENCEPHALITIS; GENE DELETION; GENE MUTATION; GENETIC MANIPULATION; GLIOBLASTOMA; HEMISPHERECTOMY; HERPES SIMPLEX VIRUS 1; HUMAN; HUMORAL IMMUNITY; INFLAMMATION; INTRACRANIAL HYPERTENSION; MAJOR HISTOCOMPATIBILITY COMPLEX; MENINGITIS; MULTIMODALITY CANCER THERAPY; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; ONCOLYTIC VIROTHERAPY; POLIOMYELITIS VIRUS; QUALITY OF LIFE; REOVIRUS; SEIZURE; VESICULAR STOMATITIS VIRUS; VIRAL GENE THERAPY; VIRUS CAPSID;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; GLIOMA; HUMANS; ONCOLYTIC VIROTHERAPY;

EID: 34247254288     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.7.4.321     Document Type: Editorial

References (23)

1. Sathornsumetee S, Rich JN. New approaches to primary brain tumor treatment. Anticancer Drugs 17(9), 1003-1016 (2006).
2. Wheeler CJ, Das A, Liu G, Yu JS, Black KL. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin. Cancer Res. 10(16), 5316-5326 (2004).
3. Giese A, Bjerkvig R, Berens ME, Westphal M. Cost of migration: invasion of malignant gliomas and implications for treatment. J. Clin. Oncol. 21(8), 1624-1636 (2003).
4. Dandy WE. Removal of right cerebral hemisphere for certain tumors with hemiplegia. JAMA 90, 823-825 (1928).
5. Kuruppu D, Tanabe KK. Viral oncolysis by herpes simplex virus and other viruses. Cancer Biol. Ther. 4(5), 524-531 (2005).
6. Shah AC, Benos D, Gillespie GY, Markert JM. Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas. J. Neurooncol. 65(3), 203-226 (2003).
7. Pulkkanen KJ, Yla-Herttuala S. Gene therapy for malignant glioma: current clinical status. Mol. Ther. 12(4), 585-598 (2005).
8. McCormick F. Cancer-specific viruses and the development of ONYX-015. Cancer Biol. Ther. 2(4 Suppl. 1), S157-S160 (2003).
9. Vecil GG, Lang FF. Clinical trials of adenoviruses in brain tumors: a review of Ad-p53 and oncolytic adenoviruses. J. Neurooncol. 65(3), 237-246 (2003).
10. Alemany R. Cancer selective adenoviruses. Mol. Aspects Med. 28(1), 42-58 (2007).
11. Rein DT, Breidenbach M, Curiel DT. Current developments in adenovirus-based cancer gene therapy. Future Oncol. 2(1), 137-143 (2006).
12. Hedley SJ, Chen J, Mountz JD et al. Targeted and shielded adenovectors for cancer therapy. Cancer Immunol. Immunother. 55(11), 1412-1419 (2006).
13. Merrill MK, Bernhardt G, Sampson JH, Wikstrand CJ, Bigner DD, Gromeier M. Poliovirus receptor CD155-targeted oncolysis of glioma. Neuro-oncol. 6(3), 208-217 (2004).
14. Dobrikova EY, Florez P, Gromeier M. Structural determinants of insert retention of poliovirus expression vectors with recombinant IRES elements. Virology 311(2), 241-453 (2003).
15. Gromeier M, Lachmann S, Rosenfeld MR, Gutin PH, Wimmer E. Intergeneric poliovirus recombinants for the treatment of malignant glioma. Proc. Natl Acad. Sci. USA 97(12), 6803-6808 (2000).
16. Gromeier M, Bossert B, Arita M, Nomoto A, Wimmer E. Dual stem loops within the poliovirus internal ribosomal entry site controlneurovirulence. J. Virol. 73(2), 958-964 (1999).
17. Ochiai H, Campbell SA, Acher GE et al. Targeted therapy for glioblastoma multiforme neoplastic meningitis with intrathecal delivery of an oncolytic recombinant poliovirus. Clin. Cancer Res. 12(4), 1349-1354 (2006).
18. Advani SJ, Mezhir JJ, Roizman B, Weichselbaum RR. ReVOLT: Radiation-Enhanced Viral Oncolytic Therapy. Int. J. Radiat. Oncol. Biol. Phys. 66(3), 637-646 (2006).
19. Fulci G, Breymann L, Gianni D et al. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc. Natl Acad. Sci. USA 103(34), 12873-12878 (2006).
20. Pulkkanen KJ, Yla-Herttuala S. Gene therapy for malignant glioma: current clinical status. Mol.Ther. 12(4), 585-598 (2005).
21. Rainov NG, Ren H. Clinical trials with retrovirus mediated gene therapy - what have we learned? J. Neurooncol. 65(3), 227-236 (2003).
22. Eisenberger A, Elliott BM, Kaufman HL. Viral vaccines for cancer immunotherapy Hematol. Oncol. Clin. North Am. 20(3), 661-687 (2006).
23. Harrop R, John J, Carroll MW. Recombinant viral vectors: cancer vaccines. Adv. Drug Deliv. Rev. 58(8), 931-947 (2006).